Blood flow studies have shown that in diabetes the retinal blood flow increases markedly with progress of background retinopathy, decreasing finally where proliferative retinopathy, with marked ...

Opens in a new tab or window Use of empagliflozin (Jardiance) was not linked to a lower risk of incident nonproliferative diabetic retinopathy compared with dipeptidyl peptidase-4 (DPP-4 ...

AAO: American Academy of Ophthalmology; CDA: Canadian Diabetes Association; DM: Diabetes mellitus; ISPAD: International Society for Pediatric and Adolescent Diabetes; NHMRC: National Health and ...

A recent French study reported that aromatic amines in hair dye are associated with development of retinopathy, 1 according to Nicolas Chirpaz, MD, first author, from the Ophthalmology Department, ...

Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, did not reduce the risk for incident nonproliferative diabetic retinopathy compared with dipeptidyl peptidase 4 (DPP-4 ...

This project uses MobileNetV2 to detect Diabetic Retinopathy (DR) and classify its severity. It supports binary (DR vs. No DR) and multiclass (Mild, Moderate, Proliferative_DR, Severe) classifications ...

Aromatic amines in hair dye are linked to retinopathy, mimicking MEK inhibitor-associated retinopathy, with symptoms resolving after discontinuation. A 61-year-old woman experienced bilateral SRDs and ...

unimelb.edu.au Background and aims: Alport syndrome is an inherited disease with renal failure, and often a hearing loss, lenticonus and dot-and-fleck retinopathy. A retinal “lozenge” or “dull macular ...

The global prevalence of diabetes continues to rise, projected to impact 700 million individuals by 2045. This increase parallels a significant growth in diabetes-associated complications, with ...

Health professionals are warning people to look out for a red flag symptom of a diabetes that shows up in the eyes. The NHS has highlighted that blurred vision could be an indicator of diabetes ...

Fintel reports that on December 23, 2024, William Blair downgraded their outlook for Applied Therapeutics (NasdaqGM:APLT) ...